Xiaoling Li

20080132444, Jun 5, 2008

Sep 29, 2005

11/663608

Xiaoling Li - Danville CA, US
Bhaskara Jasti - Stockton CA, US
Ravichandran Mahalingam - Stockton CA, US

A61K 47/30
A61K 38/02
A61K 47/36
A61K 47/44
A61P 27/00
A61K 47/38
A61K 38/13

514 11, 5147723, 514 2, 514781, 514780, 514777, 514779

This invention is directed to novel ocular agent delivery systems and, in particular, emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.

20100216700, Aug 26, 2010

Feb 22, 2010

12/710358

XIAOLING LI - Danville CA, US
Bhaskara Jasti - Stockton CA, US
Ravichandran Mahalingam - Stockton CA, US

A61K 38/13
A61K 38/16
A61P 27/02

514 11, 514 12

This invention is directed to treatments of ocular disorders using emulsions and molecular dispersions in the form of a gel comprising a hydrophobic ocular agent.

20100240029, Sep 23, 2010

Jun 6, 2007

12/303721

Leonard Guarente - Newton MA, US
Monty Krieger - Needham MA, US
Xiaoling Li - Chapel Hill NC, US

Massachusetts Institute of Technology - Cambridge MA

C12Q 1/68
C07K 14/435
G01N 33/68
C07J 9/00
C07C 59/00
C12N 15/00
G01N 33/559

435 6, 530350, 436 86, 552544, 562510, 435455, 204464

A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed.

52888274, Feb 22, 1994

Feb 17, 1993

8/018667

Xiaoling Li - Dobbs Ferry NY
Bret Berner - Scarsdale NY

Ciba-Geigy Corporation - Ardsley NY

C08F23008

526279

A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are: A. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer; B. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer, or C. (I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I, (II) 42 mole % of 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer, where formula I is ##STR1## where formula II is ##STR2## where Group A is a vinylic acid or a (meth)acrylate as defined herein. Methods of manufacture of the polymer and the use thereof as a pressure adhesive, especially a transdermal and/or transmucosal delivery system pressure sensitive adhesive, are also claimed.

53763785, Dec 27, 1994

Nov 4, 1993

8/148040

Xiaoling Li - Dobbs Ferry NY
Bret Berner - Scarsdale NY

Ciba-Geigy Corp. - Ardsley NY

A61L 1558

424448

A new polymer, the feed monomers and molar percents of which, exclusive of a polymerization initiator and crosslinker, are: A. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 16 mole % of an additional vinylic copolymerizable monomer; B. (I) 42 mole % to 58 mole % of a siloxy silane of formula I, (II) 21 mole % up to less than 42 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 29 mole % of an additional vinylic copolymerizable monomer; or C. (I) 16 mole % up to less than 42 mole % of a siloxy silane of formula I, (II) 42 mole % to 58 mole % of an unsubstituted alkyl (meth)acrylate of formula II, (III) 0 to 5 mole % of a Group A monomer, and (IV) 0 to 36 mole % of an additional vinylic copolymerizable monomer; where formula I is ##STR1## where formula II is ##STR2## in which R. sub. 3 is hydrogen or methyl; and R. sub.

20220339857, Oct 27, 2022

May 24, 2022

17/752729

- Nanjing, CN
Xiaoling LI - Dublin CA, US
Feihuang DENG - Nanjing, CN
Haohui LU - Nanjing, CN
Haili LIU - Nanjing, CN
Juan YAO - Nanjing, CN
Xiaofei WANG - Nanjing, CN
Wei WU - Nanjing, CN

B29C 64/106
B29C 64/329
B29C 64/232
B29C 64/245
B29C 64/209
B29C 64/393
B29C 64/336

A 3D printing device (), comprising a melt extrusion module (), a printing module (), and a platform module (). The melt extrusion module () comprises a processing chamber () consisting of a feed inlet () and a discharge outlet (), as well as an extrusion means () and a heating means () disposed at the processing chamber; the melt extrusion module () is configured to receive an initial material from the feed inlet () of the processing chamber (), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet () of the processing chamber (). The printing module () is communicated with the discharge outlet () of the processing chamber () and is provided with a nozzle (); the printing module () is configured to receive the molten body extruded from the discharge outlet () of the processing chamber () and guide the molten body to be extruded out of the nozzle (). The platform module () is configured to receive the molten body extruded from the nozzle ().

20220212404, Jul 7, 2022

Feb 3, 2022

17/592441

- Nanjing, CN
Feihuang DENG - Nanjing, CN
Wei WU - Nanjing, CN
Renjie LI - Nanjing, CN
Senping CHENG - Nanjing, CN
Xiaoling LI - Dublin CA, US

B29C 64/209
B33Y 10/00
B33Y 30/00
B33Y 80/00
B29C 64/245
B33Y 70/10
A61K 9/20

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of the pharmaceutical product.

20220212408, Jul 7, 2022

Feb 3, 2022

17/592443

- Nanjing, CN
Feihuang DENG - Nanjing, CN
Wei WU - Nanjing, CN
Renjie LI - Nanjing, CN
Senping CHENG - Nanjing, CN
Xiaoling LI - Dublin CA, US

B29C 64/321
B33Y 10/00
B33Y 30/00
B33Y 40/00
B29C 64/209
B29C 64/118

The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of the pharmaceutical product.